Ubiquinol as a Metabolic Resuscitator in Post-Cardiac Arrest


To determine whether external administration of ubiquinol (reduced coenzyme Q10) increases physiological ubiquinol levels and decreases markers of neurological injury.


This study is an investigator-initiated, randomized, double-blind, placebo-controlled trial of ubiquinol and placebo in post-cardiac arrest patients. A total of 48 adult patients who are resuscitated from out-of-hospital or in-hospital cardiac arrest will be enrolled at Beth Israel Deaconess Medical Center, Boston, MA, USA. Included patients will be randomized in a 1:1 ratio to either ubiquinol or placebo.


Patients in the experimental group will receive 300 mg of ubiquinol in a liquid mixture and patients in the control group will receive a liquid placebo. The intervention will be given every 12 hours for up to 7 days, until neurological recovery, or until hospital discharge.


The primary endpoint will be the absorption of ubiquinol at 24, 48, and 72 hours following randomization. Secondary endpoints include markers of neurological injury, cellular and global oxygen consumption, and clinical outcomes.


A previous pilot randomized trial demonstrated favourable neurological outcome in post-cardiac arrest patients receiving ubiquinol compared to placebo, although the findings of that trial have not been verified in any subsequent study.


Beth Israel Deaconess Medical Center (Boston, MA, USA) and Cambridge Health Alliance (Cambridge, MA, USA).